BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26905168)

  • 1. Treatment-associated severe thrombocytopenia affects survival rate in esophageal cancer patients undergoing concurrent chemoradiotherapy.
    Huang YM; Wang CH; Huang JS; Tsai CS; Yeh KY; Lan YJ; Wu TH; Chang PH; Chang YS; Lai CH
    Indian J Cancer; 2015; 52(3):454-60. PubMed ID: 26905168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
    Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
    Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of change in serum albumin level during and after chemoradiotherapy in patients with locally advanced esophageal cancer.
    Takeda K; Umezawa R; Takahashi N; Matsushita H; Kozumi M; Ishikawa Y; Yamamoto T; Takeda K; Jingu K
    Esophagus; 2018 Jul; 15(3):190-197. PubMed ID: 29951984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
    Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
    Iwase H; Shimada M; Tsuzuki T; Hirashima N; Okeya M; Hibino Y; Ryuge N; Yokoi M; Kida Y; Kuno T; Tanaka Y; Kato B; Esaki M; Urata N; Kato E
    Oncology; 2013; 84(6):342-9. PubMed ID: 23689040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
    Iwase H
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():224-9. PubMed ID: 16898007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent chemoradiotherapy for locally advanced esophageal cancer--a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil.
    Hsu CH; Yeh KH; Lui LT; Lee YC; Bu CF; Wang HP; Lin JT; Cheng AL
    Anticancer Res; 1999; 19(5C):4463-7. PubMed ID: 10650793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
    Hsu FM; Lee JM; Huang PM; Lin CC; Hsu CH; Tsai YC; Lee YC; Chia-Hsien Cheng J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e593-9. PubMed ID: 21658851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
    Ikeda E; Kojima T; Kaneko K; Minashi K; Onozawa M; Nihei K; Fuse N; Yano T; Yoshino T; Tahara M; Doi T; Ohtsu A
    Jpn J Clin Oncol; 2011 Aug; 41(8):964-72. PubMed ID: 21742654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy.
    Wu CE; Lin YC; Hong JH; Chuang CK; Pang ST; Liaw CC
    Anticancer Res; 2013 Jun; 33(6):2605-10. PubMed ID: 23749915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.
    Yoon DH; Jang G; Kim JH; Kim YH; Kim JY; Kim HR; Jung HY; Lee GH; Song HY; Cho KJ; Ryu JS; Kim SB
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):489-96. PubMed ID: 25680595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal approach for cervical esophageal carcinoma: role of neoadjuvant chemotherapy.
    Suzuki G; Yamazaki H; Ogo E; Abe T; Eto H; Muraki K; Hattori C; Umeno H; Nakashima T; Tanaka T; Nakamura S; Yoshida K
    Anticancer Res; 2014 Apr; 34(4):1989-92. PubMed ID: 24692736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
    Clavier JB; Antoni D; Atlani D; Ben Abdelghani M; Schumacher C; Dufour P; Kurtz JE; Noel G
    Dis Esophagus; 2014 Aug; 27(6):560-7. PubMed ID: 23106980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
    Rodriguez CP; Adelstein DJ; Rice TW; Rybicki LA; Videtic GM; Saxton JP; Murthy SC; Mason DP; Ives DI
    J Thorac Oncol; 2010 Feb; 5(2):229-35. PubMed ID: 20009775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes from chemoradiotherapy for patients with esophageal cancer.
    Pantling AZ; Gossage JA; Mamidanna R; Newman G; Robinson A; Manifold DK; Hale PC
    Dis Esophagus; 2011 Apr; 24(3):172-6. PubMed ID: 21073614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: magnetic resonance evaluation.
    Hatakenaka M; Yonezawa M; Nonoshita T; Nakamura K; Yabuuchi H; Shioyama Y; Nagao M; Matsuo Y; Kamitani T; Higo T; Nishikawa K; Setoguchi T; Honda H
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e67-73. PubMed ID: 22365626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy.
    Iwase H; Shimada M; Nakamura M; Nakarai K; Iyo T; Kaida S; Indo T; Kato E; Horiuchi Y; Kusugami K
    Int J Clin Oncol; 2003 Oct; 8(5):305-11. PubMed ID: 14586756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
    Yamashita H; Haga A; Takenaka R; Kiritoshi T; Okuma K; Ohtomo K; Nakagawa K
    Radiat Oncol; 2016 Jan; 11():4. PubMed ID: 26781439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.